Personalized treatment discussions for children with juvenile arthritis
Treating Children With Arthritis According to Their Individual Probability of Outcomes and Response to Treatments
This study is trying to see if having personalized treatment discussions between doctors and families can help children who are newly diagnosed with juvenile arthritis make better decisions about their care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 842 (estimated) |
| Ages | 1 Year to 18 Years |
| Sex | All |
| Sponsor | University of British Columbia Academic / other |
| Locations | 1 site (Vancouver, British Columbia) |
| Trial ID | NCT05310799 on ClinicalTrials.gov |
What this trial studies
The PERSON-JIA Trial is a cluster-randomized trial that evaluates the effectiveness of Shared Decision Making (SDM) between physicians and families for children newly diagnosed with Juvenile Idiopathic Arthritis (JIA). The intervention involves structured discussions guided by personalized outcome reports generated from prediction algorithms, which provide insights into expected disease severity and treatment effectiveness. By utilizing data from previous cohorts, the trial aims to enhance treatment tailoring and disease control through informed decision-making. The study also incorporates a registry for real-time data entry to support ongoing patient management.
Who should consider this trial
Good fit: Ideal candidates include children newly diagnosed with JIA who are being treated by participating pediatric rheumatologists in Canada.
Not a fit: Patients who have been diagnosed with JIA for more than a month or those already receiving treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective treatment plans for children with juvenile arthritis.
How similar studies have performed: Other studies have shown promise in using shared decision-making approaches, but this specific application with personalized prediction algorithms is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Physicians (Inclusion): 1. Licensed to practice pediatric rheumatology in Canada; 2. Providing care for children with JIA at least once a month; 3. Consent to be randomized and to implement the SDM intervention for the duration of the trial, if randomized to the intervention arm; 4. Commit to propose enrollment in the Registry to all their newly diagnosed patients with JIA during the trial. Physicians (Exclusion): 1. Fellows-in-training; 2. Physicians planning to retire within 2 years. Patient (Inclusion): 1. Consent to include their information in the CAPRI JIA Registry; 2. Consent to the PERSON-JIA trial and answering additional questionnaires to assess decision making; 3. Allow recording of their medical encounter (if selected at random); 4. JIA fulfilling International League of Associations for Rheumatology (ILAR) criteria; 5. Newly diagnosed (within the last month); 6. Diagnosed by a pediatric rheumatologist participating in the PERSON-JIA study; 7. Not yet receiving treatment, or received only Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) or joint injections; Patient (Exclusion): 1. Systemic arthritis category of JIA (it requires a different treatment approach); 2. Family is unable to complete study forms in English or French; 3. Patients who have already started systemic corticosteroid or any Disease Modifying Anti-Rheumatic Drug (DMARD).
Where this trial is running
Vancouver, British Columbia
- BC Children's Hospital — Vancouver, British Columbia, Canada (Recruiting)
Study contacts
- Principal investigator: Lori B Tucker, MD — University of British Columbia Department of Pediatrics
- Study coordinator: Jaime Guzman
- Email: jguzman@cw.bc.ca
- Phone: 604 875 2000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.